Literature DB >> 1804802

Terephthalamidine: past and future.

J S Fisherman1, E M Cline, J Plowman, F R Quinn, M J Hawkins.   

Abstract

Terephthalamidine (NSC 57155) is one of 800 terephthalanilides and related compounds which were synthesized and tested preclinically in the late 1950's and early 1960's. Based upon their activity against murine leukemias, some of these agents were tested briefly in clinical trials at that time. Despite the observation of responses, the compounds were dropped because of severe and unusual neurotoxicity. More recently, terephthalamidine has been screened for antitumor activity and chosen for further clinical investigation by the NCI's Project for the Review of Old Drugs (P.R.O.D.) because of its novel structure and spectrum of preclinical activity. The current availability of a plasma assay for the drug permits further study of its clinical pharmacokinetics and pharmacodynamics and, perhaps, the development of improved scheduling strategies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804802     DOI: 10.1007/BF00183569

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  13 in total

1.  High-performance liquid chromatographic determination of terephthalamidine in plasma.

Authors:  W R Waud; D L Hill
Journal:  J Chromatogr       Date:  1988-03-04

2.  Comparative studies of drug uptake, viability, and biosynthetic capabilities of P388 cells treated with "active" or "inactive" terephthalanilides.

Authors:  D W Yesair; P S Thayer; C J Kensler
Journal:  Ann N Y Acad Sci       Date:  1971-07-23       Impact factor: 5.691

3.  Drug-binding macromolecular lipids from L1210 leukemia tumors.

Authors:  R F Taylor; L A Teague; D W Yesair
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

4.  The effect of two carcinostatic agents on the chemically induced stimulation of amino acid incorporation in a mammalian system.

Authors:  W R Jondorf; A Spector; S J Chaiken
Journal:  Biochem Biophys Res Commun       Date:  1965-09-22       Impact factor: 3.575

5.  Toxicology of anti-leukemic agents with special reference to phthalanilide derivatives.

Authors:  C J Kensler; P E Palm; H M Day; S P Battista; W I Rogers; D W Yesair; I Wodinsky
Journal:  Cancer Res       Date:  1965-10       Impact factor: 12.701

6.  The antimitochondrial action of 2-choloro-4', 4"-bis(2-imidazolin-2-yl)terephthalanilide and methylglyoxal bis(guanylhydrazone).

Authors:  M J Pine; J A DiPaolo
Journal:  Cancer Res       Date:  1966-01       Impact factor: 12.701

7.  Relationship of phthalanilide-lipid complexes to uptake and retention of 2-chloro-4',4"-di(2-imidazolin-2-yl)terephthalanilide (NSC 60339) by sensitive and resistant P388 leukemia cells.

Authors:  D W Yesair; F A Kohner; W I Rogers; P E Baronowsky; C J Kensler
Journal:  Cancer Res       Date:  1966-02       Impact factor: 12.701

8.  PREVENTION BY SULFONIC AND PHOSPHORIC ANALOGS OF THE TEREPHTHALANILIDE INHIBITION OF LEUKEMIA P815Y IN VITRO.

Authors:  J H BURCHENAL; V C GREGG; S P LANCASTER; R HIRT; R BERCHTOLD; R FISCHER; R BALSIGER
Journal:  Cancer Res       Date:  1965-05       Impact factor: 12.701

9.  In vitro and in vivo studies of the antileukemic action of n,n'-bos [p-(n'-methylamidino)phenyl]terephthalamidine, tetrahydrochloride (NSC 57155) on P815 leukemic cells.

Authors:  A Winkler; W Kreis; V C Gregg; J R Purple; J H Burchenal
Journal:  Cancer Res       Date:  1966-07       Impact factor: 12.701

10.  CLINICAL INVESTIGATION OF THE PHYSIOLOGIC DISPOSITION OF A PHTHALANILIDE (NSC-38280) AND A PHTHALAMIDINE DERIVATIVE (NSC-57155) IN 7 PATIENTS.

Authors:  W KREIS; R R ELLISON; M S LYMAN; J H BURCHENAL
Journal:  Cancer Res       Date:  1965-04       Impact factor: 12.701

View more
  1 in total

1.  A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.

Authors:  G I Rodriguez; J G Kuhn; G Weiss; P De La Cruz; P New; S M Fields; J R Eckardt; L Campbell; G M Clark; S G Hilsenbeck; D D Von Hoff
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.